Ciliatech Presents Preliminary 1-Year Study Results on Treating Open and Narrow Angle Glaucoma with CID

Ciliatech announced it will present at the Ophthalmology Futures Symposium the preliminary results of a 1-year study of its clinical trial, SAFARI III, involving both open and narrow angle glaucoma patients.

Preliminary outcomes show an excellent performance and safety profile, with very few, mild, adverse events reported, according to Ciliatech. Results indicate that the company's glaucoma implant CID (Cilioscleral Interpositioning Device) works similarly for patients with primary open angle glaucoma (POAG), and primary narrow angle glaucoma, also called primary angle closure glaucoma (PACG), without the need to remove the lens. This is a potential significant benefit in Ciliatech’s cilioscleral approach. 

A cohort of 57 patients participated in the SAFARI III clinical trial, with similar numbers of open and narrow angle patients. At the 12-month postoperative visit, IOP was reduced by more than 41% (23.5 mmHg at baseline down to 13.9 mmHg at M12). Pharmacological treatments were reduced by more than 92% (mean medication dropped from 1.7 at baseline to 0.1 at M12). At 12 months, 86% of patients reported being medication-free.

“The preliminary SAFARI III results are exciting. In addition to avoiding endothelial cells loss, CID is the first minimally invasive surgical device that shows substantial promise in benefitting both open and narrow angle glaucoma patients," Olivier Benoit, CEO of Ciliatech, said in a company news release. "This is a paradigm shift for narrow angle patient care. They will now have the possibility of postponing more invasive and old-fashioned incisional therapies and can take advantage of the performance and the safety that CID offers in treating their glaucoma.

SAFARI III study

Lilit Voskanyan, MD, PhD, head of the glaucoma department in ophthalmology at the Malayan Center in Yerevan, Armenia, operated on 57 patients from June to December 2022. The study cohort was composed of two sub-groups of equal proportions of POAG and PACG patients.

Patients enrolled had glaucoma with IOP >21mmHg, uncontrolled by medications. Operations were performed as a stand-alone procedure (i.e., not combined with cataract). Patients were seen at baseline, with follow-up visits for safety and performance control scheduled at regular intervals.
 
Ophthalmology futures symposium presentation:

• ‘CID and cilioscleral surgical approach clinical outcomes – 12-month follow-up results on PACG patients’
• Speaker: Olivier Benoit, CEO of Ciliatech
• Thursday, September 7, at 09:30 – Hilton Danube Waterfront Hotel